Enicepatide Delivers Glycemic and Weight Reduction in Phase 2
Roche reported that once weekly enicepatide met both primary endpoints in the randomized Phase 2 CT 388 104 study. At 24 mg, mean HbA1c fell 2.65 percentage points and body weight fell 15.5 percent…
